The FDA has said it will reduce the regulatory requirements on the manufacturing of cell and gene therapies (CGTs) in order to make it easier for developers to bring them to market. Specifically, the ...

Gene-editing specialist Seamless Therapeutics has attracted its first major pharma partner, Eli Lilly, with a $1.12 billion alliance that will seek out therapies for hearing loss.